CTOs on the Move

Mortara Instrument

www.mortara.com

 
Founded in 1982 by David W. Mortara, PhD, Mortara Instrument was born with a guiding philosophy: design to a need, keep it simple, and make it economically accessible. Building on this philosophy, Mortara Instrument has created a complete line of
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mortara.com
  • 7865 N 86th St
    Milwaukee, WI USA 53224
  • Phone: 414.354.1600

Executives

Name Title Contact Details

Similar Companies

Accelerate Diagnostics

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The companys revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Tridien Medical

Tridien Medical is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Instruments

Advanced Instruments is a Norwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NUVO, Inc.

NUVO, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Sight Sciences

Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.